Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy
International Journal of Molecular Sciences · 02.08.2024 · 25 (15) · 8454
DOI: 10.3390/ijms25158454 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.08.2024. Verfasst von Gabriela Vochița und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Research Iasi, Branch of NIRDBS, 700107 Iasi, Romania. Hauptthemen laut MEDLINE: Liposomes, Chitosan, Nanocapsules, Anti-Inflammatory Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project contract no. 15/2020, the Core-Program developed with the support of Romanian Ministry of Research, Innovation and Digitization, NO Grants 2014-2021.
Abstract (Originalsprache)
This study describes the comparison between the interaction of a series of peptide-functionalized chitosan-based nanocapsules and liposomes with two cell lines, i.e., mouse macrophages RAW 264.7 and human endothelial cells EA.hy926. Both types of nanocarriers are loaded with magnetic nanoparticles and designed for anti-inflammatory therapy. The choice of these magnetic nanostructures is argued based on their advantages in terms of size, morphology, chemical composition, and the multiple possibilities of modifying their surface. Moreover, active targeting might be ensured by using an external magnetic field. To explore the impact of chitosan-based nanocapsules and liposomes on cell cytophysiology, the cell viability, using the MTT assay, and cell morphology were investigated. The results revealed low to moderate cytotoxicity of free nanocapsules and significant cytotoxicity induced by chitosan-coated liposomes loaded with dexamethasone, confirming its release from the delivery system. Thus, after 48 h of treatment with nanocapsules, the viability of RAW 264.7 cells varied between 88.18% (OCNPM-1I, 3.125 µg/mL) and 76.37% (OCNPM-1, 25 µg/mL). In the same conditions, EA.hy926 cell viability was between 99.91% (OCNPM-3, 3.125 µg/mL) and 75.15% (OCNPM-3, 25 µg/mL) at the highest dose (25 µg/mL), the values being comparable for both cell lines. Referring to the cell reactivity after dexamethasone-loaded liposome application, the lowest viability of RAW 264.7 cells was 41.25% (CLDM5CP-1, 25 µg/mL) and 58.20% (CLDMM2CP-1 1.25 µg/mL) in the endothelial cell line, proving a selective character of action of nanocarriers. The cell morphology test, performed to support and confirm the results obtained by the MTT test, revealed a differentiated response for the two types of nano-carriers. As expected, an intense cytotoxic effect in the case of dexamethasone-loaded liposomes and a lack of cytotoxicity for drug-free nanocapsules were noticed. Therefore, our study demonstrated the biocompatible feature of the studied nanocarriers, which highlights them for future research as potential drug delivery systems for pharmacological applications, including anti-inflammatory therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological Research Iasi, Branch of NIRDBS, 700107 Iasi, Romania.
- Faculty of Medicine, Apollonia University of Iasi, 700511 Iasi, Romania.
- Academy of Romanian Scientists, 050045 Bucharest, Romania.
- Department of Pharmaceutics, School of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, N-0316 Oslo, Norway.
- Praxis Medical Investigations, 700376 Iasi, Romania.
- Department of Molecular Genetics, Center for Fundamental Research and Experimental Development in Translational Medicine-TRANSCEND, Regional Institute of Oncology, 700483 Iasi, Romania.
ORCID-Profile: Gabriela Vochița, Anca Niculina Cadinoiu, Delia-Mihaela Rață, Leonard Ionuț Atanase, Marcel Popa, Cosmin-Teodor Mihai, Cristina-Veronica Moldovan, Elena Simona Băcăiţă, Iustina Petra Condriuc
Förderung
- Project contract no. 15/2020
- the Core-Program developed with the support of Romanian Ministry of Research, Innovation and Digitization
- NO Grants 2014-2021
- Romanian Ministry of Research, Innovation and Digitization
Zitieren
APA
Vochița, G., Cadinoiu, A. N., Rață, D. M., Atanase, L. I., Popa, M., Mahdieh, A., Mihai, C. T., Stache, A. B., Moldovan, C. V., Băcăiţă, E. S., Condriuc, I. P., & Gherghel, D. (2024). Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy. International Journal of Molecular Sciences, 25(15), 8454. https://doi.org/10.3390/ijms25158454
Vancouver
Vochița G, Cadinoiu AN, Rață DM, Atanase LI, Popa M, Mahdieh A, et al. Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy. International Journal of Molecular Sciences. 2024;25(15):8454. doi:10.3390/ijms25158454
BibTeX
@article{Vochia2024,
author = {Vochița, Gabriela and Cadinoiu, Anca Niculina and Rață, Delia-Mihaela and Atanase, Leonard Ionuț and Popa, Marcel and Mahdieh, Athar and Mihai, Cosmin-Teodor and Stache, Alexandru-Bogdan and Moldovan, Cristina-Veronica and Băcăiţă, Elena Simona and Condriuc, Iustina Petra and Gherghel, Daniela},
title = {Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8454},
doi = {10.3390/ijms25158454}
}
EUVIMED